Last reviewed · How we verify
NCT06610773
HUC-MSC for Treatment of High-risk HPV Infection
Phase 1, PHASE2 trial testing hUC-MSCs in Human Papillomavirus Viruses in 60 participants. Currently enrolling.
10 September 2025
Quick facts
| Lead sponsor | Shanghai East Hospital |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 March 2024 |
| Primary completion | 10 September 2025 |
| Estimated completion | 10 September 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- hUC-MSCs — full drug profile →
- Saline+albumin — full drug profile →
Conditions studied
- Human Papillomavirus Viruses — all drugs for Human Papillomavirus Viruses →
- Mesenchymal Stem Cells — all drugs for Mesenchymal Stem Cells →
Sponsor
Shanghai East Hospital
Who can join
Adults 25 to 60, female only, with Human Papillomavirus Viruses or Mesenchymal Stem Cells. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the safety and initial effectiveness of human umbilical cord mesenchymal stem cells in HPV clearance.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Therapeutic challenges in central nervous system viral infections: advancing mesenchymal stem cell-based strategies for treating neuroinflammation and promoting tissue repair.
Carbone-Schellman J, Fontecilla-Escobar J, Sales-Salinas N, Chaparro-Pico WF, et al · · 2025 · cited 1× · PMID 41235241 · DOI 10.3389/fimmu.2025.1677433
Verify or expand the search:
- PubMed search for NCT06610773
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of hUC-MSCs
Trials testing the same drug.
- NCT05531266 — Umbilical Cord Mesenchymal Stem Cells as First-line Treatment for Patients With Acute Graft Versus Host Disease · NA · unknown
Other recruiting trials for Human Papillomavirus Viruses
Currently open trials in the same condition.
- NCT06223568 — Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subject · Phase 2 · recruiting
- NCT05884697 — Let's K-Talk - HPV Study for Ethnic Koreans · NA · active not recruiting
Other Shanghai East Hospital trials
Trials by the same sponsor.
- NCT07519161 — Pharmacological Intervention to Prevent NOAF After TAVR · NA · not yet recruiting
- NCT07516223 — MRI-Assisted Guidance for Non-Essential Tissue Sampling · NA · not yet recruiting
- NCT07279259 — Thrombolysis in Early Acute Ischemic Stroke Trial-Blood Pressure Management · Phase 2 · recruiting
- NCT07294495 — Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Tr · NA · not yet recruiting
- NCT07290816 — Effect of Non-invasive Neuromodulation on the Quality of Intestinal Cleansing · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06610773 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai East Hospital
- Last refreshed: 24 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06610773.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing